A 10.8% to 38.4% discount. That is the gap between the IPO issuance price and the final pre-IPO perpetual price recorded on Hyperliquid’s IPOP markets across five completed cycles. The data comes from a joint letter submitted by the Hyperliquid Policy Center (HPC) and trade[XYZ] to the SEC on August 19. They claim this proves IPOPs are superior price discovery tools. What they do not state is that the same data set is their own, unaudited, and self-serving.
Proof exists; it is merely waiting to be verified. But here, the only witness is the party filing the motion.
Context: What Is an IPOP?
IPOP stands for Initial Pre-IPO Perpetual. It is a synthetic perpetual swap contract that tracks the price of a company before its public listing. The contract terminates automatically upon the IPO event. It grants no equity, no allocation rights, no voting power. It is purely a derivative—a bet on the opening price.
Hyperliquid, a high-throughput perpetual DEX running an order book model, has already hosted five complete IPOP markets. The HPC and trade[XYZ] now want the SEC to recognize this product as a legitimate, regulated instrument for price discovery. The letter outlines five regulatory concerns: classification, disclosure, listing eligibility, market integrity, and investor access.
But the technical foundation is missing. The settlement price mechanism is not disclosed. The oracle source is not specified. The liquidation logic is not audited. What we have is a product that has performed five times, according to the people who built it, and a request for permission to scale.
Core: A Systematic Teardown
Let me begin with the data. The letter highlights that the IPO issuance price was consistently lower than the final IPOP price by 10.8% to 38.4%. This is presented as evidence that underwriters underprice IPOs. That may be true. But it is also evidence that the IPOP market, with its limited liquidity and unknown participant base, may overprice. Five samples from a single platform, with no cross-validation from independent exchanges or on-chain data trails, is not a statistical argument. It is a narrative.
From my audit experience, the first rule of forensic accounting is that the party providing the numbers must have their incentives disclosed. Trade[XYZ] is likely the market maker and liquidity operator for these IPOP markets. They profit from spreads, fees, and possibly rebates. Their letter is not a disinterested public service announcement; it is a business development memo disguised as policy advocacy.
Now, the technical architecture. An IPOP is a perpetual swap with a forced termination event. The core innovation is not cryptographic; it is contractual. The underlying exchange is still Hyperliquid’s order book, which relies on a centralized sequencer and a partially disclosed validator set. The security assumption is that the settlement price is objective. But how is it determined? Is it the IPO issue price, the first trade price on the listing exchange, or a volume-weighted average of the first hour? The letter does not say.
If the settlement price is derived from an external source (e.g., Nasdaq opening print), then the IPOP contract is a prediction market on a known event. But if it is set by a single oracle or a designated market maker, manipulation becomes trivial. The 10.8%–38.4% gap could simply reflect the mark-to-market on a thin order book where a single whale could push the price before the final settlement.
Regulatory risk is the second axis. Under the Howey test, the IPOP contract likely clears the first three prongs: money invested, common enterprise (the contract depends on trade[XYZ]’s operation), and expectation of profit. The fourth prong—efforts of others—is the battleground. The price is driven by the underlying company’s fundamentals, but the contract’s mechanics, liquidity, and settlement are entirely dependent on the platform operator. This is a classic security-based swap, falling under SEC and CFTC joint jurisdiction. The algorithm remembers what the witness forgets: the code does not exempt the product from securities law.
Further, the letter admits that “investor accessibility” is a concern. This implies that current IPOP markets are not fully open to U.S. investors. That is a compliance red flag. If the SEC investigates, the first question will be: “Were U.S. persons trading these products without registration?” The absence of KYC details in the public record suggests the answer may be unfavorable.
Contrarian: What the Bulls Got Right
To be fair, the IPOP mechanism does solve a real problem. The traditional IPO process is opaque. Underwriters set the price behind closed doors, and retail investors rarely get a fair allocation. A public, continuous price discovery mechanism, even if synthetic, could reduce information asymmetry. The five completed markets did correlate with the eventual opening price, even if the gap was large. The product is not a scam; it is a legitimate experiment in market structure.
Another point: the letter is proactive. Instead of waiting for a regulatory crackdown, HPC and trade[XYZ] are seeking guidance. This is a mature approach compared to the “ask forgiveness, not permission” ethos of many DeFi projects. If the SEC provides a safe harbor or a no-action letter, Hyperliquid could become a template for compliant on-chain derivatives.
But proactive does not mean transparent. The missing technical details, the self-reported data, and the undisclosed team structure undermine the credibility of the request. The SEC is not a product accelerator; it is a law enforcement agency. It will demand verifiable, auditable evidence, not a PowerPoint deck with five data points.
Takeaway: The Waiting Game
Ledgers balance, but ethics remain uncalculated. The IPOP letter is a signal that Hyperliquid is maturing as an ecosystem, but it is also a stress test. If the SEC responds with a request for more information—which is likely—the project will be forced to reveal its settlement oracle, its KYC procedures, and its financial backers. If the SEC remains silent, the product will continue in a gray zone, exposing U.S. traders to unregistered securities risk.
Investors should not treat this as a bullish catalyst. The real value lies in the next 90 days: watch for independent audits, oracle disclosures, and any SEC public statements. Until then, the IPOP is a well-designed product with an unresolved liability. The data is incomplete. The proof is waiting to be verified.